Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.


Generic Name: Urokinase
Class: Thrombolytic Agents
CAS Number: 9039-53-6


Thrombolytic agent; plasminogen activator isolated from human neonatal kidney cell cultures.111 122 125 136 137 153 155

Uses for Kinlytic


Lysis of acute massive PE (obstruction or substantial filling defects of ≥2 lobar pulmonary arteries or multiple segments of lungs).111 117 120 132 133 134 136 140 155

Lysis of PE accompanied by unstable hemodynamics (i.e., failure to maintain BP without supportive measures).111 117 120 132 133 134 136 140 155

Generally reserve IV thrombolytic therapy for those with acute massive PE accompanied by unstable hemodynamics (e.g., shock) who do not have major contraindications because of bleeding risk117 120 121 122 132 133 140 156 or in those with stable hemodynamics with other poor prognostic factors (e.g., marked dyspnea, anxiety, and low oxygen saturation; elevated troponin concentrations indicative of right ventricular microinfarction; echocardiographic evidence of right ventricular dysfunction; right ventricular enlargement on a chest computed-tomography scan).133 135 138 156

The American College of Chest Physicians (ACCP) suggests that thrombolytic agents with a short infusion time (e.g., 2 hours for alteplase) are preferred over those with a longer infusion time (e.g., 12 hours for urokinase)156 because of increased bleeding risk with prolonged infusion.136 143 146 Urokinase also has been effective and safe when given as a 2-hour IV infusion for PE.132 134 135 148 (See PE under Dosage.)

Confirm diagnosis of PE objectively by pulmonary angiography or lung scan (e.g., computed tomography with IV contrast).111 119 122 133 152 155

Perform a rapid risk assessment to determine if thrombolytic therapy is appropriate; irreversible cardiogenic shock may occur if therapy is delayed in patients with evidence of hemodynamic compromise.156

If thrombolytic therapy fails or is contraindicated in patients with massive PE and hemodynamic instability, pulmonary embolectomy may be required.117 120 156


Has been used in selected patients for treatment of DVT (e.g., popliteal or posterior tibial vein).117 140

ACCP suggests thrombolytic therapy be reserved for use in selected patients at low risk of bleeding who have extensive acute proximal DVT (e.g., iliofemoral DVT) with symptom onset of <14 days, life expectancy of ≥1 year, and good functional status.156 ACCP also suggests thrombolytic therapy as initial treatment in patients with severe upper extremity DVT who have recent symptom onset and low risk of bleeding.156

Coronary Artery Thrombosis and MI

Has been used for lysis of coronary artery thrombi in selected patients with acute evolving transmural MI, in conjunction with heparin and/or platelet-aggregation inhibitors (e.g., aspirin).101 102 104 105 106 107 151 (See Adjunctive Anticoagulant Therapy under Dosage and Administration.)

Clinical evaluation of IV urokinase therapy in patients with MI is limited; offers no clinical advantage over other currently available thrombolytic agents (e.g., alteplase, reteplase, tenecteplase).102 127 154

Arterial Thrombosis and Embolism

Used intra-arterially for lysis of arterial occlusions in peripheral vessels and bypass grafts in selected patients with acute (<14 days old) thromboembolic arterial ischemia.118 ACCP suggests that such therapy should be used in patients who have a low risk for development of myonecrosis and ischemic nerve damage in the affected extremity.118

Occluded IV Catheters

Restoration of patency to IV catheters, including central venous catheters, obstructed by clotted blood or fibrin.112 116

Thromboembolism Associated with Prosthetic Heart Valves

Has been used in a limited number of patients for treatment of prosthetic heart-valve thrombosis.158

ACCP suggests thrombolytic therapy for patients with right-sided prosthetic valve thrombosis and NYHA functional class III or IV heart failure and in patients with left-sided prosthetic valve thrombosis and NYHA functional class I–IV with small thrombi (<0.8 cm2).158 In patients with a large (≥0.8 cm2) left-sided prosthetic valve thrombus, ACCP suggests thrombolytic therapy if emergency surgery is not available or considered high risk.158

Kinlytic Dosage and Administration


  • Use in hospitals where recommended diagnostic and monitoring techniques are available.111 155 Observe clinical response and vital signs frequently during and after urokinase infusion.111 155


  • Initiate therapy as soon as possible (preferably within several days) after onset of symptoms of PE to achieve greatest clinical benefit;111 131 134 140 155 thrombolysis is still beneficial ≤14 days following symptom onset.124 131 134 135 136

  • Determine aPTT, hematocrit, and platelet count to assess patient's hemostatic status (e.g., determine if a serious hemostatic defect exists) prior to initiating urokinase.111 155 However, results of coagulation tests and measures of thrombolytic activity do not reliably predict either drug efficacy or risk of bleeding.111 125 152 155


  • To avoid dislodgement of possible DVT, do not take BP in lower extremities when monitoring vital signs.111 155

Adjunctive Anticoagulant Therapy for PE

  • Heparin should not be infused concurrently with urokinase in patients with PE.117 152 In patients who have received heparin, generally allow aPTT to diminish to <2 times the control value before urokinase therapy is initiated.111 155

  • To minimize risk of rethrombosis and recurrent PE following thrombolytic therapy,120 122 institute anticoagulant therapy (e.g., heparin) when the aPTT has decreased to <2 times the control value.111 136 155 Follow heparin therapy with oral anticoagulant therapy.111 136 155

Adjunctive Anticoagulant Therapy for Coronary Artery Thrombosis and MI

  • In patients with acute MI who are at high risk for systemic emboli (e.g., large or anterior acute MI, atrial fibrillation, history of embolism, known left ventricular thrombus),151 IV heparin sodium, usually 5000 units by rapid IV injection followed by a continuous IV infusion, has been administered concomitantly with or immediately following urokinase infusion.104 105 106 107


For drug compatibility information, see Compatibility under Stability.

Administer by IV infusion via a controlled-infusion device only.111 155

Also has been administered by intracoronary infusion, intra-arterial infusion, or intracatheter instillation.101 102 112 116 118 154

IV Administration

For treatment of PE, administer by IV infusion via a constant infusion pump capable of delivering a total volume of 195 mL.111 155


Reconstitute vial containing 250,000 units of urokinase by adding 5 mL of sterile water for injection without preservatives to provide a concentration of 50,000 units/mL.111 155 Gently roll and tilt vial until lyophilized powder dissolves to produce a clear or slightly straw-colored solution.155 Avoid shaking to minimize formation of filaments.111 155 Presence of such filaments does not indicate any decrease in potency;111 155 such solutions may be filtered through ≤0.45-mcm cellulose membrane filter.111 155


Following reconstitution, dilute further with 0.9% sodium chloride or 5% dextrose injection to yield a final infusion volume of 195 mL.111 155

Rate of Administration

PE: Infuse at 90 mL/hour over 10 minutes (loading dose), then 15 mL/hour for 12 hours (maintenance dosage).111 117 155 To ensure delivery of entire dose, flush IV tubing with a volume of compatible diluent equal to that of tubing volume at a rate of 15 mL/hour.111 155

PE: Has also been administered as a 2-hour IV infusion.132 134 135 148 (See PE under Dosage.)

Coronary artery thrombosis and MI: Administer 50% or 100% of the dose over 5 minutes as a rapid IV injection and the remainder, if any, as a continuous infusion over 45–90 minutes.104 105 106 107


Dosage of urokinase is expressed in international units (units);111 155 biologic activity determined using an in vitro lysis assay.a



Loading dose: Initially, 4400 units/kg over 10 minutes recommended by manufacturer.111 117 155

Maintenance dosage: 4400 units/kg per hour for 12 hours recommended by manufacturer.111 155 To ensure delivery of entire dose, flush IV tubing with a volume of 0.9% sodium chloride or 5% dextrose injection equal to that of tubing volume.111 155

Repeat administration as necessary.155

Has also been administered in a dosage of 3 million units over 2 hours, with initial 1 million units infused over 10 minutes.132 134 135 148

Coronary Artery Thrombosis and MI

2–3 million units has been administered over 45–90 minutes, with 50% or 100% of the dose given as an initial rapid IV injection (e.g., over 5 minutes) and the remainder, if any, as a continuous infusion.104 105 106 107

Cautions for Kinlytic


  • Active internal bleeding.111 152 155

  • Recent (≤2 months) cerebrovascular accident.111 152 155

  • Recent trauma, including CPR.111 155

  • Known bleeding diathesis.111 155

  • Severe uncontrolled arterial hypertension.111 155

  • Intracranial neoplasms.111 152 155

  • Intracranial vascular disease (i.e., aneurysm, arteriovenous malformation).111 152 155

  • Recent (≤2 months) intracranial or intraspinal surgery.111 155

  • Known hypersensitivity to urokinase or any ingredient in the formulation.111 155



Effects on Hemostasis

Possible bleeding and hemorrhagic complications, including intracranial hemorrhage and other major bleeding complications.111 120 126 133 134 137 155 May be more common in geriatric patients, patients with renal or hepatic dysfunction, and those receiving intense or prolonged antithrombotic therapy.133 136

Weigh increased risks of therapy against anticipated benefits in patients with recent (≤10 days) major surgery, obstetric delivery, organ biopsy, previous puncture of noncompressible vessels, cerebrovascular disease (other than contraindicated conditions), hemostatic defects (e.g., secondary to severe hepatic or renal disease), recent (≤10 days) serious GI bleeding, high likelihood of left heart thrombus (e.g., mitral stenosis with atrial fibrillation), pregnancy, diabetic hemorrhagic retinopathy, or subacute bacterial endocarditis.111 155 Weigh risks against benefits in patients with any condition in which bleeding constitutes a substantial hazard or would be especially difficult to manage because of its location.111 155

Minimize risk of bleeding by carefully selecting patients and monitoring all potential bleeding sites (e.g., sites of all cutdowns; arterial, venous, and other needle punctures; catheter insertion sites).111 134 155 Avoid IM injections and nonessential handling of patient.111 134 155 Perform invasive venous procedures as carefully and as infrequently as possible.111 134 136 155 Avoid arterial invasive procedures;a use upper extremity artery (radial or brachial) if arterial puncture is essential.111 155 Apply pressure to puncture site for ≥30 minutes, apply pressure dressing, and check site frequently for evidence of bleeding.111 155

Severe and fatal spontaneous (e.g., cerebral, retroperitoneal) bleeding has occurred.111 120 126 133 134 137 155

Internal bleeding with urokinase may be more difficult to control than that which occurs with conventional anticoagulant therapy.111 155 Possible lysis of fibrin deposits that provide hemostasis (e.g., at sites of needle punctures, cuts); bleeding from such sites may result.125 126 134

If serious spontaneous bleeding occurs, immediately discontinue urokinase therapy.111 133 134 152 155 Initiate appropriate hemostatic therapy as needed (e.g., plasma volume expanders other than dextrans, packed RBCs, cryoprecipitate, fresh frozen plasma) to replace blood volume deficits and/or reverse bleeding tendency.111 134 152 155 a

Concomitant Antithrombotic Therapy

Concomitant use with other thrombolytic agents, anticoagulants, or agents inhibiting platelet function may increase risk of serious bleeding.111 155 (See Specific Drugs under Interactions.)

Do not use aspirin and other NSAIAs that inhibit platelet function for treatment of fever (e.g., fever associated with infusion reactions).111 (See Sensitivity Reactions under Cautions.)

Cholesterol Embolization

Cholesterol embolization and associated serious complications reported rarely in patients receiving thrombolytic therapy, including urokinase.111 155 Possibly fatal cholesterol embolization associated with invasive vascular procedures (e.g., cardiac catheterization, angiography, vascular surgery) and/or anticoagulant agents.111 155 Clinical features of cholesterol embolism include livedo reticularis, “purple toe” syndrome, acute renal failure, gangrenous digits, hypertension, pancreatitis, MI, cerebral infarction, spinal cord infarction, retinal artery occlusion, bowel infarction, and rhabdomyolysis.111 155

Risk of Transmissible Agents in Serum-derived Preparations

Potential vehicle for transmission of human viruses (e.g., HIV, hepatitis B virus [HBV], hepatitis C virus [HCV], human T-lymphotropic virus [HTLV], cytomegalovirus [CMV], human papilloma virus [HPV], Epstein-Barr virus [EBV]) or other infectious agents.111 155

Despite application of a number of viral elimination/reduction steps (e.g., heat treatment in solution, purification, screening for certain viruses) to prevent transmission of infectious agents, risk of transmission still remains.111 155

Report all infections thought possibly to have been transmitted by urokinase to the manufacturer at 866-634-6279.111 155

Risk of Creutzfeldt-Jakob Disease

Formulation contains 5% albumin.111 155 May carry a remote risk of transmitting causative agent of Creutzfeldt-Jakob disease (CJD).111 155 Currently, no evidence of transmission of CJD via albumin component.111 155

Sensitivity Reactions

Possible anaphylaxis; rare fatalities.111 134 155 Other allergic-type reactions (e.g., orolingual edema, bronchospasm, urticaria) reported.111 134 155

Acute infusion reactions, including fever, chills or shaking chills (rigors), hypotension, nausea, vomiting, hypoxia, cyanosis, dyspnea, tachycardia, hypertension, acidosis, and/or back pain, may occur; such reactions generally begin ≤1 hour after treatment initiation.111 134 155

If infusion reactions occur, immediately discontinue therapy, monitor patient closely, and institute appropriate therapy (e.g., IV antihistamines, adrenergic agents, corticosteroids).111 155 (See Concomitant Antithrombotic Therapy under Cautions.)

Specific Populations


Category B.111 155


Not known whether urokinase is distributed into milk.111 155 Use caution.111 155

Pediatric Use

Safety and efficacy of urokinase not established.111 155

Thrombolytic therapy generally not recommended for treatment of venous thromboembolism in neonates and children unless vessel occlusion is severe and causes organ dysfunction or limb ischemia.157 If thrombolysis is required, ACCP states that alteplase is the drug of choice in pediatric patients because of greater fibrin specificity, lower immunogenicity, and more effective clot lysis in vitro compared with urokinase.157

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether such patients respond differently than younger adults.111 155 Use with caution.111 155

Common Adverse Effects

Bleeding.111 155

Interactions for Kinlytic

Specific Drugs





Increased risk of hemorrhage111 155

Monitor carefully for evidence of bleeding111 155

GP IIb/IIIa inhibitors

Increased risk of hemorrhage111 155

Monitor carefully for evidence of bleeding111 155


Increased risk of hemorrhage111 155

Concurrent use not recommended in patients with PE111 117 152 (see Adjunctive Anticoagulant Therapy under Dosage and Administration)

If used, monitor carefully for evidence of bleeding111 155

NSAIAs (e.g., aspirin)

Increased risk of hemorrhage111 155

Do not use for treatment of fever (e.g., infusion reactions)111 155

If used, monitor carefully for evidence of bleeding111 155

Thrombolytic agents

Increased risk of hemorrhage111 155

Monitor carefully for evidence of bleeding111 155

Kinlytic Pharmacokinetics



PE: Clinical improvement and measurable hemodynamic changes may occur within a few hours but may not be observed until 6–8 hours after treatment initiation.a


PE: Fibrinolytic effects usually disappear within a few hours.111 155 Decreased plasma concentrations of fibrinogen and plasminogen and increased circulating concentrations of degradation products of fibrinogen and fibrin may persist for 12–24 hours after discontinuance of IV infusion.111 155


Elimination Route

Rapidly cleared by liver.111 155 Small amount of urokinase eliminated in urine and feces via biliary excretion.111 122 155


12.6 minutes.111 155

Special Populations

Pharmacokinetics not characterized in patients with hepatic impairment.111 155 Endogenous urokinase-type plasminogen activator plasma concentrations are elevated twofold to fourfold in patients with moderate to severe cirrhosis; hepatic impairment might be expected to reduce clearance of urokinase.111 155




Powder for Injection

Refrigerate at 2–8°C.111 155


For information on systemic interactions resulting from concomitant use, see Interactions.


Drug Compatibility

Do not mix with other drugs for IV infusion.111 155


  • Directly activates conversion of fibrin-bound and circulating plasminogen to proteolytic enzyme plasmin.111 136 144 145 153 155 Plasmin degrades fibrin, fibrinogen and other clotting factors, and other plasma procoagulant proteins.111 144 145 153 155

  • Decreases plasma concentrations of fibrinogen and plasminogen and increases circulating concentrations of degradation products of fibrinogen and fibrin.111 155

  • Exhibits less fibrin selectivity than alteplase, reteplase, and tenecteplase.117 152 153 151 May lyse fibrin deposits that provide hemostasis (e.g., at sites of needle punctures, cuts); bleeding from such sites may result.117 125 126 134

  • Degradation of fibrinogen and fibrin and other clotting factors induces anticoagulant effect.a 151 152 153

Advice to Patients

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.111

  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs.111

  • Importance of advising patients of other important precautionary information.111 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Urokinase powder for injection, formerly marketed as Abbokinase (Abbott Laboratories), has been rebranded as Kinlytic after completion of stability studies on existing inventory to extend the expiration dating.154 Urokinase injection may continue to be available from some suppliers as Abbokinase until that inventory is exhausted.154 Hospitals should deplete their current stocks of Abbokinase before using Kinlytic.154



Dosage Forms


Brand Names



For injection, IV infusion

250,000 units

Abbokinase (heat-treated, wet method)


Kinlytic (heat-treated, wet method)


AHFS DI Essentials. © Copyright 2017, Selected Revisions December 1, 2010. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


Only references cited for selected revisions after 1984 are available electronically.

100. Abbott Laboratories. Abbokinase prescribing information. Chicago, IL; 1988 Mar.

101. Tennant SN, Dixon J, Venable TC et al. Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase. Circulation. 1984; 69:756-60. [PubMed 6607784]

102. Ohman EM, Harrington RA, Cannon CP et al. Intravenous thrombolysis in acute myocardial infarction. Chest. 2001; 119:253S-277S. [PubMed 11157653]

103. Van Scoik S. Dear pharmacist letter regarding new formulation of Abbokinase (urokinase for injection). Abbott Laboratories. North Chicago, IL. 1988 Nov.

104. Mathey DG, Schofer J, Sheehan FH. Coronary thrombolysis with intravenous urokinase in patients with acute myocardial infarction. Am J Med. 1987; 83(Suppl 2A):26-30. [PubMed 3631114]

105. Neuhaus KL, Tebbe U, Gottwik M et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol. 1988; 12:581-7. [PubMed 3042835]

106. Mathey DG, Schofer J, Sheehan FH et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol. 1985; 55:878-82. [PubMed 3984876]

107. Wall TC, Phillips HR III, Stack RS et al. Results of high dose intravenous urokinase for acute myocardial infarction. Am J Cardiol. 1990; 65:124-31. [PubMed 2296881]

108. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996; 28:1328-428. [PubMed 8890834]

109. Food and Drug Administration Center for Biologics Evaluation and Research. Difficulties in obtaining sufficient of urokinase (Abbokinase). Rockville, MD; December 11, 1998. From FDA websit.

110. Pizzutti D. Dear Abbott customer letter regarding shortage of parenteral urokinase (Abbokinase). Abbott Park, IL: Abbott Laboratories; 1998 Dec 9.

111. ImaRX Therapeutics Inc. Abbokinase (urokinase) prescribing information. Tuscon, AR; 2006 Dec.

112. Abbott Laboratories. Abbokinase Open-Cath(urokinase for catheter clearance) prescribing information (dated 1999 Jan). In: Physicians’ desk reference. 54th ed. Montvale, NJ: Medical Economics Company Inc; 2000:404.

113. Zoon KC. Dear healthcare provider letter: Important drug warning: safety information regarding the use of Abbokinase (urokinase). Rockville, MD: US Food and Drug Administration; 1999 Jan 25. From FDA web site.

114. Food and Drug Administration Center for Biologics Evaluation and Research. Update on Abbokinase (urokinase). Rockville, MD; March 22, 1999. From FDA web site.

115. Abbott Laboratories, Chicago, IL: Personal communication.

116. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (NKF-DOQI) clinical practice guideline 7. Prevention and treatment of catheter and port complications. 2006 update. From NKF website. Accessed 2007 Feb 12.

117. Buller HR, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2004; 126(Suppl):401S-28S. [PubMed 15383479]

118. Sobel M, Verhaeghe R.. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133(Suppl):815S-43S. [PubMed 18574279]

119. Piazza G, Goldhaber SZ. Acute pulmonary embolism. Part I: epidemiology and diagnosis. Circulation. 2006; 114:28-32.

120. Piazza G, Goldhaber SZ. Acute pulmonary embolism. Part II: Treatment and prophylaxis. Circulation. 2006; 114:42-7.

121. Wan S, Quinlan DJ, Agnelli G et al. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism. A meta-analysis of the randomized controlled trials. Circulation. 2004; 110:744-9. [PubMed 15262836]

122. Sasahara AA, Hyers TM, Cole CM et al. The urokinase pulmonary embolism trial: a national cooperative study. Summary, conclusions, and recommendations. Circulation. 1973; 47 (Suppl 2):7-12.

123. Dong B, Jirong Y, Liu G et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2006, Issue 2. Article No.: CD004437. DOI: 10.1002/14651858.CD004437.pub2.

124. Sasahara AA, Cannilla JE, Belko JS et al. Urokinase therapy in clinical pulmonary embolism: a new thrombolytic agent. N Engl J Med. 1967; 277:1168-73. [PubMed 6058604]

125. Tow DE, Wagner HN Jr, Holmes RA. Urokinase in pulmonary embolism. N Engl J Med. 1967; 277:1161-7. [PubMed 6058603]

126. Anderson DR, Levine MN. Thrombolytic therapy for the treatment of acute pulmonary embolism. Can Med Assoc J. 1992; 146:1317-24. [PubMed 1555162]

127. Rossi P, Bolognese L. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol. 1991; 68:585–92.

128. Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA. 1970; 214:2163-72. [PubMed 5536580]

129. Hyers TM, Stengle JM, Sherry S. Treatment of pulmonary embolism with urokinase: results of clinical trial (Phase 1). Circulation. 1970; 42:979-80. Editorial. [PubMed 5492546]

130. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study JAMA. 1974; 229:1606-13.

131. Daniels LB, Parker JA, Patel SR et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol. 1997; 80:184-8. [PubMed 9230156]

132. Dalen JE, Alpert JS, Hirsh J. Thrombolytic therapy for pulmonary embolism. Is it effective? When is it indicated? Arch Intern Med. 1997; 157:2550-6. Editorial.

133. Hyers TM. Venous thromboembolism. Am J Respir Crit Care Med. 1999; 159:1-14. [PubMed 9872811]

134. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism. A comprehensive review of current evidence. Chest. 1999; 115:1695-1707. [PubMed 10378570]

135. Goldhaber SZ. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemost. 2001; 86:444-51. [PubMed 11487035]

136. Riedel M. Venous thromboembolic disease. Acute pulmonary embolism 2: treatment. Heart. 2001; 85:351-60. [PubMed 11179282]

137. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Chest. 2002; 122:1801-7.

138. Goldhaber SZ. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: Pro. Arch Intern Med. 2005; 165:2197-9. Commentary. [PubMed 16246980]

139. Thabut G, Logeart D. Thrombolysis for pulmonary embolism in patients with right ventricular dysfunction: Con. Arch Intern Med. 2005; 165:2200-3. Commentary. [PubMed 16246981]

140. Emmerich J, Meyer G, Decousus H et al. Role of fibrinolysis and interventional therapy for acute venous thromboembolism.Thromb Haemost. 2006; 96:251-7. [PubMed 16953264]

141. Meyerovitz MF, Goldhaber SZ, Reagan K et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology. 1990; 175:75–8.

142. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg. 1994; 220:251–68.

143. Goldhaber SZ, Kessler CM, Heit J et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet. 1988; 2(8606):293-8. [PubMed 2899718]

144. Lijnen HR, Collen D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb Haemost. 1995; 74:387-90. [PubMed 8578491]

145. Bell WR. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3 Suppl 2:S34-44.

146. Gold HK, Johns JA, Leinbach RC et al. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plamsminogen activator in patients with unstable angina pectoris. Circulation. 1987; 75:1192-9. [PubMed 3105913]

147. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). From ACC website.

148. Goldhaber SZ, Kessler CM, Heit JA et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992; 20:24-30. [PubMed 1607532]

149. Meyer G, Sors H, Charbonnier B et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol. 1992; 19:239-45. [PubMed 1732347]

151. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 guidelines for the Management of Patients with Acute Myocardial Infarction). 2004. Available from ACC website. Accessed 2008 Mar 6.

152. Marder VJ. The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med. 1979; 90:802-8. [PubMed 434689]

153. Weitz JI, Stewart RJ, Fredenburgh JC. Mechanism of action of plasminogen activators. Throm Haemost. 1999; 82:974-82.

154. ImaRX Therapeutics, Tucson, AZ: Personal communication.

155. ImaRX Therapeutics Inc. Kinlytic (urokinase) for injection prescribing information. Tucson, AZ; 2007 June.

156. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133 (Suppl): 454S-545S. [PubMed 18574272]

157. Monagle P, Chalmers E, Chan A et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133:887S-968S. [PubMed 18574281]

158. Salem DN, O'Gara PT, Madias C et al. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008; 133:593S-629S. [PubMed 18574274]

a. AHFS Drug Information 2008. McEvoy GK, ed. Urokinase. Bethesda, MD: American Society of Health-System Pharmacists; 2008:1553-6.